

As Moderna's COVID-19 Vaccine Takes the Lead, The Issue of "Gene-editing Vaccines"

By <u>Whitney Webb</u> Global Research, May 22, 2020 <u>The Last American Vagabond</u> 18 May 2020 Region: <u>USA</u> Theme: <u>Biotechnology and GMO</u>, <u>Intelligence</u>, <u>Science and Medicine</u>

More and more frequently, government officials, political pundits and self-appointed "global health experts" like billionaire Bill Gates have been instructing the public that mass gatherings and any semblance of "normalcy" will not return until a vaccine for the novel coronavirus Covid-19 is created and subsequently distributed to the masses. In recent weeks, it has quickly become apparent that the leading Covid-19 vaccine candidate is the messenger RNA (mRNA) vaccine being developed by Boston-based Moderna Inc.

Today, Moderna announced that its vaccine candidate, named mRNA-1273, "**appeared** to produce an immune response in **eight people** who received it." Moderna's response is odd given that the "study" in question is focused on safety and "is actually not designed to measure effectiveness of the vaccine," according to <u>a report in *TIME*</u>. Notably, none of the study's findings on vaccine safety were reported aside from claims it was "generally safe." It is also worth noting that this "safety-focused" study only began in March and thus, to date, represents only an examination of the vaccine's effects in the very short term.

Major media outlets in <u>multiple countries</u> ran with the headlines trumpeting that Moderna's Covid-19 vaccine "<u>shows promising early results</u>" and has presented "encouraging early signs" because of its purported ability to produce Covid-19 antibodies in humans. In addition, these media reports failed to raise other simple yet necessary questions such as how a sample size of only eight people can translate into scientific findings of any real significance without further testing involving larger sample sizes. They also failed to note that the study in question *is not even finished* as <u>a U.S. government press release</u> noted that the findings in question are merely "interim results." In addition, the study is being led by the U.S.' National Institute of Allergy and Infectious Diseases (NIAID), itself headed by Dr. Anthony Fauci, who is a key figure in the U.S. government's coronavirus response.

Though it is unclear if these "<u>encouraging early signs</u>" will be replicated in future tests of larger samples that are actually designed to test the vaccine's effectiveness, the news is surely welcome to Moderna, given that their past mRNA vaccines <u>failed to produce</u> hardly any immune response at all, explaining why the company has never brought an mRNA vaccine to market in its entire history as a company.

However, since at least last fall, Moderna has sought to resolve this issue by adding "nanoparticles" to its mRNA vaccine, <u>a modification financed by</u> the Pentagon's Defense Advanced Research Projects Agency (DARPA). Moderna is a "<u>strategic ally</u>" of DARPA and has received millions from DARPA and the Bill and Melinda Gates Foundation <u>several years</u> <u>prior</u> to the current coronavirus crisis. DARPA's plans for nanoparticles and nanotechnology and their potentially Orwellian applications were the subject of <u>a recent *The Last American*</u>

Vagabond report.

Thanks to the "interim results" of this new study, Moderna is set to take the lead in the race to gain government approval for a Covid-19 vaccine. Moderna had already pulled ahead of other Covid-19 vaccine candidates in recent weeks, being the first vaccine in the U.S. to go the human trials (after it was allowed to skip animal trials) and also enjoying strong support from the U.S. government. For instance, Moderna's Covid-19 vaccine recently received fast-track approval from the Food and Drug administration (FDA) after receiving the "green light" to proceed to Phase 2 testing prior to the results of Phase 1 being published. Moderna's president, Dr. Stephen Hoge, recently said the company now expects to begin the final third phase of testing sometime this summer.

In addition to support from the FDA, Moderna has also received considerable U.S. government funding (<u>\$438 million</u>) from the Biomedical Advanced Research and Development Authority (BARDA), a division of HHS overseen by HHS' Assistant Secretary for Preparedness and Response (ASPR) **Robert Kadlec**. Moderna <u>has also stated</u> that it is directly collaborating with the U.S. government to bring its vaccine candidate to market.

Moderna's considerable lead has also been the result of backing that it <u>received in January</u> from the Coalition for Epidemic Preparedness Innovations (CEPI), which was founded in 2017 by the governments of Norway and India along with the World Economic Forum (WEF) and the Bill and Melinda Gates Foundation. Moderna's Covid-19 vaccine has also received <u>additional millions</u> from long-time Moderna backer Bill Gates. Gates <u>recently authored an</u> <u>article</u> where he described Moderna's mRNA vaccine for Covid-19 as the "most exciting" and discussed it at length.

Gates' affinity for Moderna may owe to the fact that Moderna's co-founder, MIT's Robert Langer, is a Gates associate <u>whose lab developed</u> the Gates-funded "quantum dot 'tattoo'" vaccine identification marker that is "visible using a special smartphone camera app and filter" and was described by *Science Alert* as "a low-risk tracking system." Another Langer-Gates partnership is a "<u>birth control microchip</u>" inserted to the body that releases contraceptives and can be turned on and off wirelessly.

Gene Editing

With Moderna taking a firm lead relative to the other Covid-19 vaccine hopefuls, it is worth taking a closer look at the man who has overseen its development, Moderna's current Chief Medical Officer, **Dr. Tal Zaks**. Zaks who began his career at GlaxoSmithKline, oversees "preclinical development, clinical development and regulatory affairs" for Moderna and all of its subsidiaries.

In a 2017 TED Talk, two years after joining Moderna, Dr. Zaks spoke at length about how he views mRNA vaccines and their modality, including those he produces at Moderna. In a speech entitled "The disease-eradicating potential of gene editing," Dr. Zaks' description of Moderna's mRNA products as, making permanent edits to human genes, clashes with <u>claims</u> that the genetic material in mRNA vaccines "degrade" over time and do not permanently alter human genetics like DNA vaccines.

Beginning his talk, Zaks states that Moderna and similar companies "are actually hacking the software of life and that it's changing the way we think of and treat disease." He describes mRNA as "critical information that determines what a cell will actually do" and then states that, if one could "introduce a line of code or change a line of code" in a person's genome, that has "profound implications for everything."

The summary of Zaks' talk encapsulates his view as the following simple question:

"If our cells are the hardware and our genetic material the operating system, what if we could change a few lines of code?"

It also says that Zaks considers the future of "personalized medicine" to be "gene-editing vaccines tailored to each patient's immune system."

The Ted Talk recommended after viewing Zaks' speech on the Ted Talk website notably broaches a key point that Zaks overlooks, namely that gene-editing can "change an entire species – forever."

Zaks' statements are noteworthy and concerning for several reasons, including the fact that DARPA — Moderna's "strategic ally" — is also openly funding research aimed at "reprogramming genes" and "manipulat[ing] genes or control[ling] gene expression to combat viruses and help human bodies withstand infection" caused by Covid-19.

The DARPA-backed project would use a method that is known to cause <u>severe genetic</u> <u>damage</u> that has actually been shown to aggravate the conditions it was meant to cure.

With such permanent gene-altering technology on the fast-track to become the first Covid-19 vaccine widely available for use, it is deeply concerning that this experimental vaccine with potentially far-reaching consequences is being rammed through thanks to fervent support from both the U.S. government and controversial philanthropists that apparently have little interest in studies examining the mRNA vaccine's long-term effects.

Given that the stage <u>has already been set</u> for mandatory vaccinations that will be "distributed" throughout the U.S. <u>by the military</u>, now is the time to vigorously raise awareness about the Moderna vaccine's gravely under-reported ability to "hack the software of life" in ways that could harm public health.

*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

All images in this article are from The Last American Vagabond

The original source of this article is <u>The Last American Vagabond</u> Copyright © <u>Whitney Webb</u>, <u>The Last American Vagabond</u>, 2020

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Whitney Webb

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca